参考文献

[1]le Roux CW, Astrup A,Fujioka K,et al.3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised,doubleblindtrial.[J].Lancet.2017,389(10077):1399-1409.

[2]Narayanaswami V,Dwoskin LP. Obesity: Current and potential pharmacotherapeutics and targets.[J].Pharmacolther.2017,170:116-147.

[3]Smith SR, Garvey WT, Greenway FL,　et al. Coadministration of lorcaserin and phen-termine for weight management: a 12-week, randomized, pilot safety study. Obesity 2017,25:857-865.

[4]Zhao H ,Jiao L.Comparative analysis for the effect of Roux-en-Y gastric bypass vs sleeve gastrectomy in patients with morbid obesity: Evidence from 11 randomized clinical trials (metaanalysis).[J].Int J Surg.2019,72:216-223.(https://www.daowen.com)

[5]Khan Z,Khan　MA, Hajifathalian K, et al.Efficacy of Endoscopic Interventions for the Management of Obesity: a Meta-analysis to Compare Endoscopic Sleeve Gastroplasty, AspireAssist, and Primary Obesity Surgery Endolumenal.[J].Obes Surg.2019,29(7):2287-2298.

[6]kramuddin S, Blackstone RP, Brancatisano A, et al. Effect of reversible　intermittent intra-abdominal vagal nerve blockade on morbid obesity the recharge randomized clinical trial. JAMA. 2014;312(9):915–922.

[7]Danilla S,Babaitis RA,Jara RP,et al.High-Definition Liposculpture: What are the Complications and How to Managethem?[J].Aesthetic Plast Surg. 2020,44(2):411-418.

[8]Sullivan S,Edmundowicz SA,Thompson,CC.Endoscopic Bariatric and Metabolic Therapies:New and Emerging Technologies. [J]. Gastroenterology. 2017,152(7) :1791-1801.